{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:39:06Z","timestamp":1794245946682,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,16]],"date-time":"2011-04-16T00:00:00Z","timestamp":1302912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10928-011-9198-0","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T04:57:32Z","timestamp":1302843452000},"page":"369-383","source":"Crossref","is-referenced-by-count":20,"title":["Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation"],"prefix":"10.1007","volume":"38","author":[{"given":"Anita","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Z.","family":"Benet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,16]]},"reference":[{"key":"9198_CR1","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","volume":"25","author":"S Sahin","year":"2008","unstructured":"Sahin S, Benet LZ (2008) The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25:2869\u20132877","journal-title":"Pharm Res"},{"key":"9198_CR2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763\u2013766","journal-title":"J Clin Pharmacol"},{"key":"9198_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00547132","volume":"32","author":"DM Hamby","year":"1994","unstructured":"Hamby DM (1994) A review of techniques for parameter sensitivity analysis of environmental models. Environ Monit Assess 32:135\u2013154","journal-title":"Environ Monit Assess"},{"key":"9198_CR4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","volume":"5","author":"E Perucca","year":"1978","unstructured":"Perucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D (1978) Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 5:495\u2013499","journal-title":"Br J Clin Pharmacol"},{"key":"9198_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1345\/aph.1G617","volume":"40","author":"S Dutta","year":"2006","unstructured":"Dutta S, Reed RC, O\u2019Dea RF (2006) Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets\u2014clinical implications. Ann Pharmacother 40:619\u2013625","journal-title":"Ann Pharmacother"},{"key":"9198_CR6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0091270004266782","volume":"44","author":"S Dutta","year":"2004","unstructured":"Dutta S, Reed RC, Cavanaugh JH (2004) Absolute bioavailability and absorption characteristics of Divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 44:737\u2013742","journal-title":"J Clin Pharmacol"},{"key":"9198_CR7","unstructured":"Goldkind L, Bashaw D The essentials of \u201cdosing interval\u201d [PowerPoint slides]. U.S. Food and Drug Administration. www.fda.gov\/ohrms\/dockets\/ac\/02\/slides\/3873S2_02_Goldkind-Bashaw.ppt"},{"key":"9198_CR8","unstructured":"Committee for Proprietary Medicinal Products (2002) Note for Guidance on clinical investigation of medicinal products for treatment of nociceptive pain. The European Agency for the Evaluation of Medicinal Products, London, UK"},{"key":"9198_CR9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.31.5.510","volume":"31","author":"DE Mager","year":"2003","unstructured":"Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510\u2013518","journal-title":"Drug Metab Dispos"},{"key":"9198_CR10","first-page":"401","volume":"35","author":"B Meibohm","year":"1997","unstructured":"Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic\/pharmacodynamic (PK\/PD) modelling. Int J Clin Pharmacol Ther 35:401\u2013413","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9198_CR11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","volume":"29","author":"M Danhof","year":"2008","unstructured":"Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186\u2013191","journal-title":"Trends Pharmacol Sci"},{"key":"9198_CR12","volume-title":"Physicians\u2019 desk reference","author":"ER Depakote","year":"2007","unstructured":"Depakote ER (2007) Physicians\u2019 desk reference. Thomson PDR, Montvale, NJ"},{"key":"9198_CR13","unstructured":"Charney DS, Mihic SJ, Harris RA (2006) Hypnotics and sedatives. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, Chapter 16. McGraw-Hill, New York, pp 403\u2013427"},{"key":"9198_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/j.1552-4604.1984.tb02782.x","volume":"24","author":"A Locniskar","year":"1984","unstructured":"Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI (1984) Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. J Clin Pharmacol 24:255\u2013263","journal-title":"J Clin Pharmacol"},{"key":"9198_CR15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s002280050233","volume":"51","author":"HG Schaefer","year":"1997","unstructured":"Schaefer HG, Heinig R, Ahr G, Adelmann H, Tetzloff W, Kuhlmann J (1997) Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 51:473\u2013480","journal-title":"Eur J Clin Pharmacol"},{"key":"9198_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/157340208786241273","volume":"4","author":"C Hocht","year":"2008","unstructured":"Hocht C, Mayer MA, Opezzo JAW, Bertera FM, Taira CA (2008) Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 4:289\u2013302","journal-title":"Curr Hypertens Rev"},{"key":"9198_CR17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200241020-00005","volume":"41","author":"C Csajka","year":"2002","unstructured":"Csajka C, Buclin T, Fattinger K, Brunner HR, Biollaz J (2002) Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet 41:137\u2013152","journal-title":"Clin Pharmacokinet"},{"key":"9198_CR18","unstructured":"drugs@FDA, FDA Approved Drug Products. U.S. Food and Drug Administration. www.accessdata.fda.gov\/scripts\/cder\/drugsatfda"},{"key":"9198_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00228-006-0228-6","volume":"63","author":"HS Lim","year":"2007","unstructured":"Lim HS, Cho JY, Oh DS, Chung JY, Hong KS, Bae KS, Yu KS, Lee KH, Jang IJ, Shin SG (2007) Angiotensin II type 1 receptor 1166A\/C polymorphism in association with blood pressure response to exogenous angiotensin II. Eur J Clin Pharmacol 63:17\u201326","journal-title":"Eur J Clin Pharmacol"},{"key":"9198_CR20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00005344-199003000-00013","volume":"15","author":"E Blychert","year":"1990","unstructured":"Blychert E, Hedner T, Dahl\u00f6f C, Elmfeldt D (1990) Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol 15:428\u2013435","journal-title":"J Cardiovasc Pharmacol"},{"key":"9198_CR21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s002280050317","volume":"52","author":"P Muller","year":"1997","unstructured":"Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H (1997) Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 52:441\u2013449","journal-title":"Eur J Clin Pharmacol"},{"key":"9198_CR22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","volume":"3","author":"S Oparil","year":"2001","unstructured":"Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 3:283\u2013291 318","journal-title":"J Clin Hypertens"},{"key":"9198_CR23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/11531190-000000000-00000","volume":"49","author":"DR Brocks","year":"2010","unstructured":"Brocks DR, Mehvar R (2010) Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet 49:421\u2013438","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-011-9198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-011-9198-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-011-9198-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T04:56:44Z","timestamp":1559451404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-011-9198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["9198"],"URL":"https:\/\/doi.org\/10.1007\/s10928-011-9198-0","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,16]]}}}